Liraglutide
A GLP-1 receptor agonist approved by the FDA under brand names such as Victoza and Saxenda for specific medical indications.
What it is
Liraglutide is the elder statesman of the GLP-1 class — a daily-injection GLP-1 receptor agonist, FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management, with years of post-market history behind it.
Its trial record includes cardiovascular-outcome data, and its weight-loss effect, while smaller on average than semaglutide's or tirzepatide's, is well characterized. Generic versions have begun arriving, which increasingly makes it the affordability conversation within the approved GLP-1 family.
What researchers have actually studied it for
Type 2 diabetes and weight management — approved indications with large trials, cardiovascular-outcome data and long post-market experience.
How it works
Like its successors, liraglutide activates the GLP-1 receptor — slowing gastric emptying, promoting satiety and glucose-dependent insulin release. Its fatty-acid modification buys roughly a day of action rather than a week, hence daily injection.
The molecule itself
A 31-amino-acid GLP-1 analog nearly identical to the natural hormone, with a single substitution and a C16 fatty-acid chain — first-generation albumin-binding engineering that bought roughly a day of action. Its close-to-native structure made it the class's proof of concept.
Where it came from
Approved for diabetes in 2010 and for weight management in 2014, liraglutide was the drug that proved chronic GLP-1 therapy for obesity was viable — the commercial and clinical groundwork everything since built on. Its LEADER trial was also the class's first major cardiovascular-outcome win.
The timeline
2010
FDA approves Victoza for type 2 diabetes.
2014
Saxenda approved — the class's first weight-management indication.
2016
LEADER trial delivers the class's first cardiovascular-outcome win.
2024–25
Generic liraglutide begins entering the US market — a class first.
What the research record actually contains
- LEAD program: RCTs establishing glycemic efficacy in type 2 diabetes.
- SCALE program: placebo-controlled obesity trials, high-single-digit average weight reduction.
- LEADER trial: cardiovascular-outcome benefit in high-risk type 2 diabetes.
- Fifteen years of post-market experience — the longest safety record in the class.
What could change this assessment
Generic economics are its second act: as prices fall, expect renewed use where coverage fails the newer drugs, plus formulary leverage that indirectly disciplines class pricing. Its evidence file is complete and stable.
What's known about risks
The best-characterized safety profile in the class, by tenure: GI effects lead, with the same gallbladder, pancreatitis and thyroid-warning caveats as its successors. Its long real-world record is its distinctive safety asset.
Where it stands legally
Prescription-only; generic liraglutide has been entering the US market, a first for the GLP-1 class. The generic route runs through the same pharmacies and prescribers — it changes price, not process.
Worth asking a licensed provider
- 1.Does generic liraglutide meaningfully change the cost equation for me versus newer weekly options?
- 2.Is a daily injection realistic for my adherence, or does weekly dosing matter more than price?
- 3.How do the average-result differences across the class apply to my goals?
Common claims, corrected
“It's obsolete now that weekly drugs exist.”
Reality: Smaller average effect, yes — but the longest safety record in the class and a growing generic price advantage keep it clinically relevant, especially where cost decides.
“Daily dosing means it's weaker chemistry.”
Reality: It's earlier engineering, not lesser: the same albumin-binding strategy its successors refined. The molecule proved the entire class viable.
Liraglutide FAQ
Is liraglutide as effective as semaglutide?
Head-to-head and cross-trial data show smaller average weight loss than semaglutide. It compensates with the longest safety track record in the class, and generics are changing its cost story.
Why is liraglutide daily when semaglutide is weekly?
Molecular engineering: liraglutide's fatty-acid modification extends its life to about a day; semaglutide's design stretches to a week. Same receptor, different pharmacokinetics.
Is generic liraglutide available?
Generic versions have been entering the US market, making it the first GLP-1 with a meaningful generic pathway — worth discussing with a prescriber where cost is the constraint.
How much cheaper is generic liraglutide?
Pricing is settling as manufacturers enter, but generics historically land at deep discounts to brand — worth a pharmacy-benefits check before assuming the newest molecule is the only option.
Is Saxenda the same as Victoza?
Same molecule, different approved doses and indications — Victoza for diabetes, Saxenda for weight management. Coverage often follows the label.